Immunocore Holdings (6YG) Stock Overview
Engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6YG from our risk checks.
6YG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Immunocore Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.80 |
| 52 Week High | US$35.60 |
| 52 Week Low | US$23.20 |
| Beta | 0.73 |
| 1 Month Change | 21.01% |
| 3 Month Change | 7.46% |
| 1 Year Change | -1.37% |
| 3 Year Change | -49.91% |
| 5 Year Change | -0.69% |
| Change since IPO | -24.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6YG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.3% | -0.5% | 2.0% |
| 1Y | -1.4% | 17.0% | 1.2% |
Return vs Industry: 6YG underperformed the German Biotechs industry which returned 17% over the past year.
Return vs Market: 6YG underperformed the German Market which returned 1.2% over the past year.
Price Volatility
| 6YG volatility | |
|---|---|
| 6YG Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 6YG has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6YG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 524 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME.
Immunocore Holdings plc Fundamentals Summary
| 6YG fundamental statistics | |
|---|---|
| Market cap | €1.49b |
| Earnings (TTM) | -€24.15m |
| Revenue (TTM) | €361.62m |
Is 6YG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6YG income statement (TTM) | |
|---|---|
| Revenue | US$412.81m |
| Cost of Revenue | US$279.56m |
| Gross Profit | US$133.25m |
| Other Expenses | US$160.82m |
| Earnings | -US$27.57m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 32.28% |
| Net Profit Margin | -6.68% |
| Debt/Equity Ratio | 100.0% |
How did 6YG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 16:02 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunocore Holdings plc is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| William Maughan | Canaccord Genuity |
| Eric Schmidt | Cantor Fitzgerald & Co. |